• Lucie-Marie Scailteux, Claudie Guedes, Elisabeth Polard, and Aleth Perdriger.
• CHU de Rennes, centre régional de pharmacovigilance, service de pharmacologie clinique, 35000 Rennes, France. Electronic address: luciemarie.scailteux@chu-rennes.fr.
• Presse Med. 2015 Jan 1; 44 (1): 4-10.

ContextTNF α antagonists (anti-TNF α) are widely used in inflammatory rheumatic diseases: rheumatoid arthritis (RA) and spondylarthropathy (SpA). The efficacy of the anti-TNF α monoclonal antibodies was also observed in unresponsive sarcoidosis to conventional therapy. In contrast, sarcoidosis in patients with inflammatory rheumatic disease treated with anti-TNF α keep on growing, with a suspected role of anti-TNF α in this pathological process.MethodsWe presented here two cases of sarcoidosis developing while the patient was on adalimumab (ADA) therapy for inflammatory rheumatic disease. In one case, the reintroduction of ADA led to increase in symptomatology. We also analyzed the 16 other cases of sarcoidosis developing under ADA treatment published in literature, mostly in RA patients.ResultsThese cases show a possible paradoxical effect of ADA in sarcoidosis development in patients treated with anti-TNFα monoclonal antibodies. The iatrogenic mechanism remains unclear. These cases underline the importance of a drug-induced etiology survey facing any symptomatology suggesting the development of sarcoidosis in patients treated with anti-TNF α for an inflammatory rheumatic disease.Copyright © 2014 Elsevier Masson SAS. All rights reserved.

23 keywords...

hide…